Aurinia Pharmaceuticals Inc.
AUPH
$15.35
$0.171.12%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 18.87% | 24.40% | 28.81% | 8.41% | 22.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.87% | 24.40% | 28.81% | 8.41% | 22.41% |
| Cost of Revenue | 28.73% | -2.39% | 44.25% | 34.11% | 9.42% |
| Gross Profit | 16.36% | 32.36% | 15.14% | 5.75% | 26.23% |
| SG&A Expenses | -9.65% | 8.31% | -21.00% | -38.20% | -42.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -167.42% | -93.70% | -1,159.83% | -79.69% | 3,288.28% |
| Total Operating Expenses | -25.96% | -7.17% | -34.39% | -21.96% | -13.57% |
| Operating Income | 129.44% | 77.17% | 451.77% | 153.19% | 4,679.82% |
| Income Before Tax | 120.19% | 80.40% | 2,942.63% | 115.86% | 1,399.05% |
| Income Tax Expenses | 1,668.58% | 852.24% | -68,300.00% | -10.07% | -14.95% |
| Earnings from Continuing Operations | 73.91% | 47.17% | 14,651.15% | 119.87% | 2,879.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 73.91% | 47.17% | 14,651.15% | 119.87% | 2,879.64% |
| EBIT | 129.44% | 77.17% | 451.77% | 153.19% | 4,679.82% |
| EBITDA | 104.20% | 63.76% | 278.07% | 107.98% | 469.31% |
| EPS Basic | 80.31% | 54.46% | 15,717.82% | 138.68% | 3,090.00% |
| Normalized Basic EPS | 127.13% | 78.18% | 132.92% | 134.31% | 829.73% |
| EPS Diluted | 75.55% | 56.25% | 14,998.02% | 130.00% | 3,090.00% |
| Normalized Diluted EPS | 125.59% | 76.55% | 131.04% | 131.34% | 811.71% |
| Average Basic Shares Outstanding | -3.55% | -4.71% | -7.20% | -7.86% | -5.90% |
| Average Diluted Shares Outstanding | -2.91% | -3.88% | -6.44% | -6.62% | -4.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |